Article 62KPN Newly Discovered Molecule Fights Off Over 300 Kinds of Drug-Resistant Bacteria

Newly Discovered Molecule Fights Off Over 300 Kinds of Drug-Resistant Bacteria

by
BeauHD
from Slashdot on (#62KPN)
schwit1 shares a report from ScienceAlert: The molecule is called fabimycin, and further down the line it could be used to fight off some of the most stubborn infections that humans can get. The new potential treatment targets gram-negative bacteria, a group of hard-to-kill pathogens that are commonly behind infections of the urinary tract, lungs, and even the bloodstream. Their resilience is due to a protective outer membrane that helps shield the wall from damaging substances like antibiotics. One study at an English hospital found more than a third of individuals with gram-negative bacteria blood infections had died within a year, demonstrating the challenges involved in managing these robust microbes. Fabimycin overcomes these problems by passing through the outer cell layer, avoiding the pumps that remove foreign material to allow the molecule to accumulate where it can do the most harm. The substance also manages to avoid wiping out too many healthy bacteria, another issue with current treatments. The team started off with an antibiotic that was known to be effective against gram-positive bacteria and made several structural changes to give the molecule the power to infiltrate gram-negative strains' powerful defenses. In tests, fabimycin had an effect on more than 300 types of drug-resistant bacteria. What's more, in mice models it was shown to reduce levels of harmful bacteria in mice with pneumonia or urinary tract infections to where they were pre-infection. The research has been published in the journal ACS Central Science.

twitter_icon_large.pngfacebook_icon_large.png

Read more of this story at Slashdot.

External Content
Source RSS or Atom Feed
Feed Location https://rss.slashdot.org/Slashdot/slashdotMain
Feed Title Slashdot
Feed Link https://slashdot.org/
Feed Copyright Copyright Slashdot Media. All Rights Reserved.
Reply 0 comments